Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Tezspire gains FDA approval for CRSwNP, expanding AstraZeneca and Amgen’s reach in inflammatory airway diseases
Tezspire gets FDA approval for chronic rhinosinusitis with nasal polyps. See how AstraZeneca and Amgen are expanding the respiratory biologics frontier.
Is Imagion Biosystems (ASX: IBX) on the cusp of a breakout? FDA optimism lifts Phase 2 hopes, but market sentiment remains cautious
Imagion Biosystems is progressing toward a key FDA filing and Phase 2 trial for its HER2 imaging agent. Find out why IBX could be at a turning point.
Is Faron Pharmaceuticals (AIM: FARN) turning a corner? Bexmarilimab shows 85% ORR in HR-MDS as ESMO data boosts confidence
Faron Pharmaceuticals’ updated ESMO 2025 data shows 85% ORR and new biomarker insight for bexmarilimab in HR-MDS. Find out why this trial may redefine the biotech’s future.
Can Invion Limited (ASX: IVX) unlock new growth by taking Photosoft into pet cancer care?
Invion signs a new funded deal with Protect Animal Health to test Photosoft in pet cancer care. Can this pivot unlock faster returns for the ASX-listed biotech?
Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO
Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors.
Can Azitra’s ATR-01 live microbe therapy finally fix filaggrin loss in ichthyosis vulgaris?
Find out how Azitra’s ATR-01 microbe therapy could repair the root genetic defect in ichthyosis vulgaris and transform dermatology treatment.
How Celcuity Inc.’s gedatolisib trial results sent its stock soaring 46% in a single morning
Celcuity stock surged 46% after Phase 3 trial data showed strong efficacy for gedatolisib in HR+/HER2- breast cancer. Find out what this means for investors.
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises ÂŁ16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.
Neuren Pharmaceuticals secures third FDA Fast Track for NNZ-2591 as shares rise 4.21%
Find out how Neuren Pharmaceuticals is expanding FDA Fast Track coverage for NNZ‑2591 across rare disorders like PMS, AS, and Pitt Hopkins.